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A C C E P T E D M A N U S C R I P T Introduction
Neurofilaments (NFs) are major structural elements of neurons which are present in perikarya and dendrites and particularly abundant in large myelinated axons, where they are essential for the radial growth of axons during development, the maintenance of axon caliber and the velocity of nerve conduction (Hoffman et al., 1987; Hursh, 1939; Kriz et al., 2000) .
NFs are heteropolymers composed of four subunits: a triplet of NF light (NF-L), NF medium (NF-M) and NF heavy (NF-H) chains and either α-internexin or peripherin in the central and peripheral nervous systems, respectively (Yuan et al., 2012) . These heterodimers polymerize to form NFs which interact with cytoskeleton proteins, such as microtubules (Miyasaka et al., 1993) .
Accumulation of NFs has been reported in several neurological diseases, such as in amyotrophic lateral sclerosis (ALS) where ectopic accumulation of NFs is found in the cell bodies and proximal parts of motor neurons (Corbo and Hays, 1992; Hirano, 1991) .
Accumulation of abnormally phosphorylated NFs has also been reported in Lewy bodies of
Parkinson's disease (PD) patients (Bancher et al., 1989; Hill et al., 1993) and in neurofibrillary tangles of Alzheimer's disease (AD) patients (Leigh et al., 1989) . Several studies have also reported that soluble NF subunits can be detected in the cerebrospinal fluid (CSF) and that increased CSF NF-L levels are associated with neuronal death and axonal degeneration in AD patients (Rosengren et al., 1996; Scherling et al., 2014; Skillbäck et al., 2014; Skillbäck et al., 2013) , Parkinson-plus syndromes, such as multiple system atrophy (MSA) and progressive supranuclear palsy (PSP) (Constantinescu et al., 2010; Hall et al., 2012; Herbert et al., 2015; Holmberg et al., 1998) , frontotemporal dementia (FTD) (Landqvist Waldo et al., 2013; Meeter et al., 2016; Rosengren et al., 1996; Scherling et al., 2014 ), Huntington's disease
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5 (Constantinescu et al., 2009 ), ALS and Multiple Sclerosis (MS) (Soelberg Sorensen and Sellebjerg, 2016) .
In ALS patients, an increase in CSF NF-L correlates with the conversion from bulbar/spinal to generalized ALS (Tortelli et al., 2015) and in MS an increase in CSF NFs has been shown to be a surrogate marker for neuro-axonal damage (Giovannoni and Nath, 2011) . Moreover, CSF NF-L levels are elevated in patients with different stages of MS and in relapsing versus remitting forms of MS (Kuhle et al., 2013; Lycke et al., 1998; Malmestrom et al., 2003; Norgren et al., 2004; Semra et al., 2002) . In addition, in patients with the relapsing form of MS, CSF NF-L levels are reduced after 6 to 12-months treatment with Natalizumab (Gunnarsson et al., 2011) . Taken together, these data suggest that increased CSF NF-L levels could be a biomarker of the neurodegenerative process that could be used to stratify patients and to monitor the progression of neurodegeneration and the efficacy of neuroprotective therapies.
NF-L has also been detected in human blood using a highly sensitive electrochemiluminescent assay (Gaiottino et al., 2013; Limberg et al., 2016) or SIMOA technology (Rohrer et al., 2016; Rojas et al., 2016) . Serum NF-L has been shown to be increased in Clinical Isolated Syndrome (CIS) (Disanto et al., 2015) and in early relapsing remitting MS where it correlates with NF-L levels in CSF (Kuhle et al., 2016) . Moreover, serum NF-L can discriminate between ALS and healthy controls (Gaiottino et al., 2013; Lu et al., 2015) , differentiate PD from atypical PD (Hansson et al., 2017) , predict disease progression in PSP (Rojas et al., 2016) and be used as a prognostic biomarker for the clinical onset and severity in FTD (Meeter et al. 2016) . A strong correlation between serum NF-L and CSF NFlevels has also been reported (Rojas et al., 2016; Meetler et al., 2016; Hansson et al., 2017) .
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In another recent publication (Bacioglu et al., 2016) , CSF and blood levels of NF-L were also evaluated in murine models of alpha-synucleinopathies, tauopathy, and ß-amyloidosis and were reported to be increased in conjunction with the appearance of proteopathic lesions and axonal pathology.
In the present study, we have evaluated whether NF-L levels in CSF or blood can be used as a biomarker of neurodegeneration in an inducible transgenic mouse model of neurodegeneration, the CamKII-TetOp25 model (referred to as p25 mice) (Cruz et al., 2003) .
In this model, prolonged p25 expression causes severe synaptic and neuronal loss and brain atrophy which are accompanied by cognitive deficits (Cruz et al., 2003; Fischer et al., 2005) .
Repression of p25 transgene expression stops global brain atrophy, neuronal loss and astrogliosis, suggesting that the pathogenesis in this model can be regulated by switching on and off p25 expression (Fischer et al., 2005) . We have used the ability to induce and switch off neurodegeneration in p25 mice to evaluate the kinetic profile of NF-L levels in CSF and serum. Our data demonstrate that increased levels of NF-L in the CSF and blood correlate with induced neuronal damage in the cortex and hippocampus of p25 mice and that the NF-L measured in the CSF is probably a cleaved form of NF-L.
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Material and methods

Animals
All mice in this study were produced and provided by Charles River (France CamKII-TetOp25 mice (p25 mice) were generated, as described by Cruz et al. (Cruz et al., 2003) . Briefly, p25 bitransgenic mice were generated using the tetracycline-controlled transactivator system to express human p25 under the control of a CamKII promoter, which drives high p25 transgene expression in the forebrain. In the presence of the tetracycline derivative, doxycycline, expression of the p25 transgene is repressed. All the mice in this study, including littermate controls, were exposed to doxycycline in utero and maintained on a doxycycline containing diet until 6 weeks of age, at which point doxycycline was removed from their diet to induce expression of the p25 transgene. This event is, hereafter, referred to as "induction". HexHe genotype refers to bitransgenic animals (p25 mice), whereas WtxHe genotype corresponds to littermate controls (control mice) that are non-inducible monotransgenic mice carrying only the TetO-p25 transgene. The very low level of p25 expression in control mice is similar to the level of p25 detected in non-induced p25 mice (data not shown).
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Study design parameters
Both male and female mice were used in this study. There were no a priori specific exclusion criteria, other than animal health and ethical standards. The numbers of mice per group were based on the size of the animal batches and on preliminary data, but no power calculation or sample size determination was performed. No statistical randomization schedule was used, but induction start (removal of doxycycline from diet), biofluids and tissue sampling was organized so that, at the end of the experiment, samples from each group were equally distributed during sampling.
CSF and blood sampling
Animals were anesthetized with an intraperitoneal injection of a mixture of ketamine hydrochloride (50mg/kg) and xylazine (10mg/kg). CSF was sampled, as previously described (DeMattos et al., 2002) . Briefly, animals were placed on a platform and the arachnoid membrane covering the cisterna magna was punctured. The positive flow pressure allows collection of CSF using a micropipette with a narrow tip. Five to twenty microliters of CSF per mouse were collected and stored at -80°C in polypropylene tubes. The animals were then removed from the platform and an intracardiac blood puncture performed. Blood was collected in a microvette 500-Z gel® (Sarstedt) containing a clotting activator for serum isolation. The microtubes were centrifuged for 5 min at 10,000xg and sera were collected and stored at -80°C.
Brain sampling
Brains were dissected out and one hemi-brain was kept for Western blot analysis and the other was prepared for immunohistochemistry. For Western blot analysis, cerebral cortices
were quickly frozen in cooled isopentane and then stored at -80°C. The hemi-brain used for immunohistochemistry was immersion-fixed in 4% formaldehyde for 7 days. Post-fixed hemibrains were rinsed in phosphate-buffered saline (PBS) and cryoprotected in a 20% sucrose solution and then frozen. Serial sagittal cryostat (Microm, HM560) sections were collected onto microscope glass slides (Flex, Dako) and then stored at -20°C, or placed in PBS-sodium azide 0.1% containing wells and stored at 4°C.
Histology and immunohistochemistry
Fluoro-Jade B histology was performed using an anionic fluorescein derivative dye as a marker of cells undergoing degeneration (Schmued et al., 1997) . For this purpose, 14 µm cryostat sections were directly mounted onto slides (Flex, Dako). The slides were first rehydrated in distilled water and then transferred to a solution of 0.06% potassium permanganate for 30 min under gentle agitation on a rotating platform. The slides were then rinsed and incubated in a 0.0004% Fluoro-Jade B solution prepared in 0.1% acetic acid (AG310, Chemicon). Slides were then rinsed and rapidly air-dried on a slide warmer (50°C).
Finally, the slides were cleared by immersion in xylene for at least 1 min before coverslipping with Eukitt mounting media.
Immunohistochemistry of RNA binding protein FOX-1 homolog 3 (RBFOX3), also known as neuronal nuclei (NeuN), was performed on 20 μm free-floating sections. NeuN is an RNAbinding protein localized in the nucleus and in the cytoplasm that regulates alternative splicing events, and is used as a sensitive and specific neuronal marker (Kim et al., 2009; Wolf et al., 1996) . Briefly, sections were washed in 0.1M PBS/0.15% Triton X-100 solution and incubated in 0.3% hydrogen peroxide at room temperature for 30 minutes. given group. Although the slides were coded, the observer was not blind to experimental groups when performing quantitative analyses. Data and metadata traceability was ensured
by the equipment which automatically loads and links bar-coded meta-data with the resulting virtual image.
NF-L ELISA assay
The sandwich ELISA NF-light® assay (UmanDiagnostics, Umeå, Sweden) used contains two highly specific NF-L monoclonal antibodies targeting the rod region of NF-L, with no crossreactivity with other known brain antigens: capture monoclonal antibody 47:3 and biotinylated detector monoclonal antibody 2:1 (Norgren et al., 2002; Norgren et al., 2003) .
The ELISA was run as described in the NF-light® assay instructions, with the following adaptation: CSF samples (5-20 µL) were diluted in a final volume of 100 µL. For sera, 50 µL was assayed in a final volume of 100 µL. Due to the small volumes of CSF samples and in order to avoid variability across plates, all samples from a given study were randomized and run on a single ELISA plate. The absorbance was read at 450 nm with a VersaMax microplate reader (Molecular Devices). A 4-parameter logistic regression was performed to provide the best curve fit using Softmax® Pro software. Results are expressed as ng/L of CSF or serum.
The detection level of the assay was around 1.5 pg/well (corresponding to 31 ng/L when 50 µL was assayed).
Spike recovery in human CSF has already been documented (see Instructions for Use version 2016/04 from NF-light® assay), with recovery yield of 88-99 % in the interval 250 -2500 ng/L.
We also performed spike recovery testing in Wt mouse serum: following addition of known amounts of NF-L to 50µl of serum per well, the recovery yield was 62-70 % in the interval 1000-5000 ng/L (supplementary data, Fig. S1 ).
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Western Blot
Evaluation of p25-GFP protein expression in cerebral cortex
Tissues were lysed in RIPA buffer (Cell Signaling), containing protease and phosphatase inhibitors (ThermoScientific), in Precellys tubes (CK14). After lysis, samples were centrifuged at 14,000 × g for 10 min at 4°C and the supernatants stored at −80°C.
Protein concentration was determined using DC Protein® Assay (Biorad). Equal amounts of total proteins were submitted to Western blot analysis with the Novex® NuPAGE® gel electrophoresis system, according to manufacturer's instructions (Life Technologies). Proteins were denatured in LDS buffer containing DTT and then loaded onto a NuPAGE® 4-12% BisTris Mini gel to perform the electrophoresis. Proteins were then transferred to polyvinylidene difluoridine (PVDF) membranes (0.45µm, Life Technologies). Membranes were blocked with TBS / Tween 20 0.1% / BSA 5% and incubated overnight at 4°C with a rabbit polyclonal primary antibody raised against the C-terminal of p35 (C-19) (Santa Cruz) followed by an incubation with an anti-rabbit IgG HRP-conjugated secondary antibody (GE Healthcare) for 1h at room temperature in TBS / Tween 20 0.1% /Milk 5%. Immuno-reactive proteins were revealed using an electrochemiluminescence detection kit (GE Healthcare). The electrochemiluminescent signal was captured with a high-resolution CCD camera LAS-3000 (Fujifilm) and densitometry measured with MultiGauge software. To allow quantification across several gels, one sample was used as an internal calibrator and was loaded on each gel and set to 100%.
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Evaluation of CSF NF-L
To enrich samples in NF-L before Western blot evaluation and to eliminate high amounts of albumin, which migrates very close to NF-L (data not shown), CSF NF-L or recombinant bovine NF-L were first immuno-captured by incubating samples for 1h in the ELISA plate from the NF-light® assay which is coated with an antibody against-NF-L (capture monoclonal antibody 47:3). Then, after washing, 25µL of boiled LDS buffer containing DTT was added to the wells for 10 minutes at 70°C. Denatured samples containing the immuno-captured NF-L were then subjected to SDS-PAGE analysis. NF-L proteins were revealed using a rabbit monoclonal antibody raised against NF-L as a primary antibody (Cell Signaling, C28E10) and an anti-rabbit IgG HRP-conjugated as a secondary antibody (GE Healthcare).
Statistics
Statistical analyses were conducted using SAS 9.2 (SAS Institute Inc., Cary, NC, USA), and graphs were generated using GraphPad Prism® version 5 for Windows (GraphPad Software, San Diego, CA , USA).
ON study
In the exploratory ON study ( 
ON-OFF study
In the ON-OFF study (Fig. 2, 3 and 4) , data from 12 Ctl (6 males and 6 females) and 60 p25
mice (30 males and 30 females) were analysed; 1 animal died before CSF sampling. The effect of the duration of p25 transgene induction and the impact of switching off p25 transgene expression were analysed in p25 male mice only. Further details on statistical analysis are provided in Supplementary Methods.
In addition, Spearman correlation coefficients were calculated between the parameter "CSF NF-L" and the parameters "brain weight", "p25-GFP", "serum NF-L", "NeuN" and "Fluoro-Jade B", respectively. Spearman correlation coefficients were also calculated between the parameter "Serum NF-L" and the parameters "NeuN" and "Fluoro-Jade B".
ROC curves
Receptor Operating Characteristic (ROC) curve analysis of CSF and serum NF-L levels were analysed according to Robin et al. (Robin et al., 2011) . Further details on statistical analysis and optimal threshold determination are provided in Supplementary Methods.
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Results
CSF and serum NF-L levels increase upon p25 transgene induction
We first assessed the effect of different time periods of p25 transgene induction (ON) on p25-GFP protein levels in the cerebral cortex. Figure 1A shows that p25-GFP protein was maximally expressed after 3 weeks of p25 transgene induction (3wON) in both male and female mice, with higher levels in male mice, and then progressively declined with robust expression still detected after 6 weeks of induction. As previously reported by Cruz et al. (Cruz et al., 2003) , induction of p25 induced a significant brain atrophy as revealed by the decrease (-13%) in brain weights in both male and female p25 mice after 3 weeks of p25 transgene induction (Fig. 1B ). Brain atrophy increased with induction duration (reduction of brain weights of -23% and -19% after 6 weeks of induction in male and female p25 mice, respectively). This increase in brain atrophy probably explains, at least in part, the decrease of p25 protein expression in the cortex.
CSF NF-L levels were significantly increased following induction of p25 at all-time points tested, with CSF NF-L levels being higher in male mice than in female mice ( (-47%) and 19,478 ng/L (-27%) in female and male mice, respectively (global significant difference, all animals included, observed between 4 and 6wON: p=0.0355). In two separate experiments on female mice, after 10 weeks of induction, CSF NF-L was also significantly reduced (-58% and -46%) in comparison to 5wON (data not shown).
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No significant correlation was found between CSF NF-L levels and p25-GFP protein levels in the cerebral cortex (r=0.224, p=0.1764), suggesting that the increase of NF-L levels is not directly linked to p25 transgene expression, but is a secondary consequence of mechanism(s) induced by p25 overexpression (i.e., neuronal death of p25 expressing neurons or synaptic loss). There was also no significant correlation between brain weights and CSF NF-L levels (r=-0.198, p=0.2267).
The concentrations of serum NF-L, which were at least 20-fold lower than CSF NF-L levels, also increased in p25 mice after p25 transgene induction ( Fig. 1D ) but did not change between 3 and 5wON. The increase in serum and CSF NF-L levels were significantly correlated (r=0.353, p=0.0277, Fig. 1E ). Three animals appear to be outside of the correlation scatter plot. These mice (1 female and 2 male) were in the 3wON group and showed higher serum NF-L levels (> 1000 ng/L) in comparison to all other mice. Such high serum NF-L levels should be taken with caution since they were not confirmed in the following ON-OFF study.
The increase in CSF NF-L levels is stopped when p25 transgene is switched off
To evaluate the sensitivity of CSF NF-L levels to p25 expression, p25 transgene expression was switched off after 2 or 3 weeks of p25 induction for a period of 3 or 2 weeks (2wON+3wOFF and 3wON+2wOFF, respectively) ( Fig. 2A) . Since both p25-GFP protein expression and CSF NF-L levels were consistently higher in male mice than in female mice (Fig. 1A) , separate experiments were performed with only male (Fig. 2B/2C ) or female mice (supplementary data, Fig. S2A/S2B ).
The overexpression of p25-GFP in the cerebral cortex was almost completely abolished when p25 transgene was switched off (Fig. 2B ) with the residual expression of p25-GFP being higher in the 3wON+2wOFF group than in the 2wON+3wOFF group (p=0.0011), suggesting
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17 that transgene turnover was ongoing but still incomplete after 2 weeks of transgene repression. The increase in CSF NF-L levels was also stopped when p25 expression was switched off (Fig. 2C) . CSF NF-L levels in animals in which p25 expression was switched off after 2 weeks of induction (2wON+3wOFF: 11,958 ng/L) or 3 weeks of induction Repression of p25 expression also prevented further increases in serum NF-L levels between 2 and 5 weeks of induction (Fig. 2D ). In this ON-OFF study, the serum NF-L levels correlated strongly with the CSF NF-L levels (r=0.794, p<0.0001; Fig. 2E ).
Ongoing neurodegeneration and neuronal loss are stopped when p25 transgene is repressed.
To evaluate ongoing neurodegeneration after p25 transgene expression, we quantified the number of Fluoro-Jade B-positive neurons in the hippocampus and in the cerebral cortical layers II and VI ( Fig. 3A/3C ). No Fluoro-Jade B-positive cells were detected in control mice, whereas significant numbers of Fluoro-Jade B-positive neurons were present in all brain areas studied after p25 induction, in agreement with data obtained in another p25 inducible transgenic mouse model (Muyllaert et al., 2008) . Staining appeared first in the DG hippocampal area and then in other hippocampal areas, CA1 and CA3, and cerebral cortex
(data not shown). The number of Fluoro-Jade B-positive positive cells was higher in the hippocampus than in the cortex (Fig. 3A) . In the CA1 hippocampal area and in the cortical layer II, the number of Fluoro-Jade B-positive cells significantly increased between 2 and 3wON (p=0.0006 for CA1, and p=0.0001 for cortex layer II), and remained stable between 3 and 5wON (Fig. 3A) . By contrast, in the cortical layer VI (Fig. 3A) , the number of Fluoro-Jade B-positive neurons increased between 2 and 3wON (p<0.0001) and continued to increase between 3 and 5wON (p=0.0057).
In the hippocampal CA1 area and in the cerebral cortical layers II and VI, switching off p25 transgene expression after 2wON (2wON+3wOFF) stopped further increases in Fluoro-Jade B staining. Fluoro-Jade B staining in the 2wON+3wOFF group was not significantly different from the 2wON group and was significantly lower (p=0.0350) than the neurodegeneration measured at 5wON. There was no difference in Fluoro-Jade B staining when comparing the 3wON+2wOFF group to the 3wON and 5wON groups, likely due to the fact that neurodegeneration process is stable in the CA1 area between 3 and 5 weeks. Similar results were obtained in the cerebral cortical layer II. However, in the cortical layer VI, although neurodegeneration progressively increased between 3 and 5wON, we failed to detect any difference between the 3wON+2wOFF and the 5wON group, suggesting that it is difficult to stop the progression of neurodegeneration after 3 weeks of p25 induction in this model, or that a 2wOFF washout period is not long enough.
We next evaluated neuronal density by measuring NeuN immuno-staining in the CA1 hippocampal area and in the cortical layers II and VI ( Fig. 3B/3D ). Upon p25 induction, neuronal loss was observed in the CA1 hippocampal area between 2 and 5 weeks of transgene induction (-30%, p=0.0031); neuronal density also appeared reduced in the
cortical layers II and VI (-28%, p=0.0580 and -25%, not significantly different from control period 2wON, respectively) (Fig. 3B ). When p25 expression was switched off after 2wON (2wON+3wOFF), neuronal staining intensity in the CA1 hippocampal area and in the cortical layer VI remained similar to the neuronal staining measured at the onset of p25 transgene repression, i.e., 2wON, and higher than the neuronal staining at 5wON (p=0.0086 and p=0.0423 respectively), suggesting that neuronal loss was stopped. These data demonstrate that switching off p25 transgene prevents further neurodegeneration and neuronal loss in the CA1 hippocampal area and cerebral cortex.
CSF and serum NF-L levels correlate with neuronal damage in p25 mice
We further evaluated whether CSF NF-L levels were correlated with neuronal damage, i.e., ongoing neurodegeneration and neuronal loss in p25 mice. In the CA1 hippocampal area and cortical layers II and VI, CSF NF-L levels were significantly (p<0.0001) and strongly correlated with ongoing neurodegeneration (r=0.788, r=0.741 and r=0.817, respectively; Fig. 4A and supplementary data, Table S1A ). CSF NF-L levels were also significantly (p<0.0001) and inversely correlated with neuronal density (r=-0.692, r=-0,672 and r=-0,559 in CA1 hippocampal area, cortical layers II and VI, respectively ( Fig. 4B and supplementary data, Table S1B ). Statistically significant correlations were found between serum NF-L levels and ongoing neurodegeneration (supplementary data, Table S1C ) or neuronal loss (supplementary data, Table S1D ). In summary, CSF and serum NF-L levels appear to be correlated with neuronal damage in the brain of p25 mice.
CSF NF-L and serum NF-L can discriminate control from induced p25 mice
To evaluate whether CSF or plasma NF-L levels could discriminate between control and p25 mice we performed a Receiver Operating Characteristic (ROC) analysis, an approach often
used for biomarker validation studies in humans. Based on 65 control and 118 p25 mice, ROC curve analysis revealed that CSF and serum NF-L levels are able to discriminate control mice from p25 mice with an excellent area under the curve (AUROC=1 and 0.97, respectively). For CSF ROC analysis (Fig. 5A) , 2,639 ng/L was determined as the optimal cut-off value and led to high sensitivity (0.991) and specificity (1). For serum ROC analysis, 100.54 ng/L was determined as the optimal cut-off value and led to a sensitivity of 0.983 and a specificity of 0.875 (Fig. 5B) .
NF-L measured in CSF is not full-length NF-L
To characterize which form of NF-L is present in the CSF of p25 mice, we performed an SDS-PAGE analysis of immuno-captured NF-L. We first validated our Western blot antibody, a monoclonal antibody (C28E10) from Cell Signaling, on brain homogenates from control and p25 mice. We easily detected full length NF-L in brain which was not modulated upon p25
induction (data not shown). To determine whether NF-L was degraded in the CSF, we spiked CSF from control mice with 120 pg of full-length recombinant bovine NF-L and measured its expression by Western blot and by ELISA after different incubation times (0, 1, 6 or 24h) at 37°C. By Western blot the fulllength NF-L signal decreased with incubation time and totally disappeared after 24h. By contrast, when using an ELISA to detect NF-L there was only a 15% decrease of NF-L levels after incubating recombinant full-length NF-L in CSF for 24h at 37°C (Fig. 6B) . Taken together, these data suggest that NF-L measured by ELISA in the CSF of p25 mice is probably not fulllength NF-L. Based on the antibodies used in this study, the cleaved form of NF-L most likely lacks the epitope recognized by the Cell Signaling antibody (around amino-acid residue 455, according to supplier information), whereas it can be detected by the two antibodies used in the UmanDiagnostics NF-light® assay.
Similarly to our observations in p25 mice, high levels of CSF NF-L were also detected by ELISA in CSF from ThyTau22 mice, another transgenic mouse model overexpressing human tau (supplementary data, Fig. S4A ), but full-length NF-L was not detected by Western blot with C28E10, the Cell Signaling anti-NF-L monoclonal antibody.
In order to better characterize which forms of NFL, full-length and/or truncated protein, are present in the CSF, we performed a mass spectrometry analysis of immuno-captured NF-L using 400µl CSF from 9-month-old Thy-Tau22 mice (corresponding to 10 ng NF-L as measured by ELISA) (supplementary methods). The immuno-captured sample was separated by SDS-PAGE and proteins were stained with Coomassie Blue dye (supplementary data, Fig. S5A ).
The gel lane was then sliced into 9 bands below 85 kDa, which were digested with
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NF-L was identified with two tryptic peptides, Q341 -K354 and E372 -K380, only in the gel band 9 at around 10 kDa (Fig. S5B) . No NF-L peptide was detected at the expected size for full-length NF-L (68kDa). Peptide E372 -K380 from NF-L is shared with Vimentin (P20152) and Desmin (P31001), two intermediate filament proteins also detected in the CSF sample but peptide Q341 -K354 is found exclusively in NF-L, strongly suggesting that the fragment around 10 kDa in gel 9 belongs to NF-L.
Taken together, these data suggest that NF-L measured by ELISA in the CSF of Thy-Tau22 mice is not the full-length NF-L, but a cleaved form of the protein (approximately 10kDa), which is nonetheless detected by the two antibodies used in the UmanDiagnostics NF-light® assay.
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Discussion
In the present study, we used a model of inducible neurodegeneration, p25 mice, to evaluate whether NF-L levels in CSF or blood could be used as potential biomarkers of neurodegeneration. Our data demonstrate that increases in both CSF and serum NF-L levels are correlated with ongoing neurodegeneration and neuronal loss in the cerebral cortex and hippocampus and that both biomarkers can discriminate control from induced p25 mice.
Moreover, when the expression of the p25 transgene is switched off, the levels of CSF NF-L do not increase further, mirroring the block of ongoing neurodegeneration and neuronal loss. The levels of CSF and serum NF-L are also correlated with the extent of neuronal damage suggesting that they could be used as dynamic biomarkers of neurodegeneration.
p25 mice are a rapid and aggressive model of neurodegeneration in brain regions where neuronal overexpression of human p25 transgene is induced (Cruz et al., 2003; Muyllaert et al., 2008) . Previous studies have shown neurodegeneration, based on whole brain atrophy and decreases in hippocampal neuronal counts, starting after 6 weeks of p25 induction (Fisher et al., 2005) , whereas our data, based on whole brain atrophy, Fluoro-Jade B staining and CSF NF-L, demonstrate that neurodegeneration can be detected as early as 3 weeks after p25 induction. By contrast, NeuN optical density in the hippocampus does not decrease before 5 weeks of p25 induction. We have also provided new data demonstrating that p25 transgene expression levels and CSF NF-L levels are higher in male than in female mice after p25 induction.
Although originally generated to explore the role of deregulated brain Cdk5 activity in triggering in vivo neurodegeneration, p25 mice display changes in several neurodegenerative mechanisms, including neuronal cytoskeletal alterations, abnormal protein
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24 hyperphosphorylation, synaptic dysfunction, cell cycle activation, DNA damage and activation of glial cells (Cruz et al., 2003; Fischer et al., 2005; Fischer et al., 2007; Kim et al., 2008; Sundaram et al., 2012) . The ability to regulate the neurodegeneration phenotype in p25 mice makes this a relevant model to evaluate candidate dynamic biomarkers of neurodegenerative processes in biofluids.
In the ON-OFF study in p25 mice the increase in CSF NF-L levels more closely correlates with the increase in Fluoro-Jade B staining than with the decrease in neuronal density, indicating that CSF NF-L could be a more sensitive biomarker of a dynamic process of neurodegeneration rather than of neuronal loss. The absence of a decrease in CSF NF-L and Fluoro-Jade B staining during the short OFF period (2 or 3 weeks) could be due to a lag time between turning off transgene expression and stopping the ongoing neurodegenerative process. We did not detect any change in full-length NF-L levels when measured by Western Blot in the hippocampus from p25 mice which could be due to a lack of sensitivity by analysing a whole homogenate.
Very high levels of CSF NF-L (25,000 ng/L) are observed after only 4 weeks of transgene induction in male p25 mice. Such high levels of CSF NF-L have also been reported in three transgenic mouse models with different proteinopathy brain lesions, including α-synuclein A30P-αS, Tau P301S and APP/PS1 mice (Bacioglu et al., 2016) . In TauP301S mice, CSF NF-L reached 40,000 ng/L in 10 to 12-month-old mice and reached 13,000ng/L in 18-month-old APPPS1 mice. We have generated similar data in comparable transgenic mouse models, i.e., ThyTau22 mice, APP/PS1 and APP mice (see supplementary data in Fig. S4 ). Bacioglu et al. (Bacioglu et al., 2016 ) also demonstrated in APP/PS1 mice that a BACE-1 inhibitor administered for six months (from 1.5 to 7.5 months) was able to reduce the increase of CSF
25 NF-L, reinforcing the view that CSF NF-L may serve as a disease progression and pharmacodynamic biomarker in preclinical mouse models.
In humans, an increase in CSF NF-L has been associated with several CNS diseases. The highest increase in CSF NF-L levels has been described after an acute ischemic stroke (19,000 ng/L in patients with severe stroke) (Hjalmarsson et al., 2014) . CSF-NF-L has also been used to stratify patients with ALS by showing that high concentrations of CSF NF-L (>5,000 ng/L) significantly correlated with disease progression and is a possible early indicator of the overall survival time (Tortelli et al., 2015) . NF-L is also increased in CSF from FTD patients (6,762 ng/L in symptomatic FTD versus 650 ng/L in control) and the level of NF-L correlates with disease severity and brain atrophy measured by MRI (Meeter et al., 2016) .
In AD and PD, CSF NF-L levels are lower than in FTD (Scherling et al., 2014) . In a large cohort study, Skillbäck et al. (Skillbäck et al., 2013) showed that AD biomarker-positive subjects have higher NF-L levels, probably linked to cerebrovascular or subcortical axonal degeneration, but
that it was more difficult to distinguish AD patients from controls >65 years old since CSF NF-L levels also increased with age (Skillbäck et al., 2014; Skillbäck et al., 2013) . More recently, Zetterberg et al. (Zetterberg et al., 2016) showed that CSF NF-L concentrations correlated with accelerated cognitive decline in MCI patients and suggested that high CSF NF-L in AD or MCI could be an indicator of risk of rapid disease progression.
CSF NF-L levels have also been shown to be decreased during immuno-modulatory treatment in both RRMS and progressive MS patients. In RRMS, treatment with fingolimod decreased NF-L levels compared with placebo and reductions in NF-L correlated with an improvment in relapse and magnetic resonance imaging outcomes (Kuhle et al., 2015a) . Natalizumab treatment in progressive MS patients also decreased CSF NF-L levels which was correlated
26 with increases in the magnetization transfer ratio in both cortical grey and normal appearing white matter and EDSS improvement (Romme Christensen et al., 2014) . Taken together, both the literature data and our results suggest that CSF NF-L could be used as a translational biomarker to following disease progression, neurodegeneration, and treatment efficacy in human neurodegenerative diseases.
Despite the high levels of CSF NF-L measured with the UmanDiagnostics NF-light® assay, we
were not able to detect full length CSF NF-L by Western blot using the Cell Signaling anti-NF-L monoclonal antibody, C28E10. This is unlikely to be due to a lack of sensitivity with Western 10kDa, containing two tryptic peptides, Q341 -K354 and E372 -K380, the first one being found exclusively in the peptidic sequence of NF-L. In the CSF, the presence of cleaved protein forms has already been documented for Tau (Meredith et al., 2013) and neurogranin (Kvartsberg et al., 2015) .
The classical ELISA assay used in our study has been described to be not sensitive enough to detect NF-L in human blood, leading to the development of a new ELISA format, based on electro-chemiluminescence detection (ECL) (Gaiottino et al., 2013; Kuhle et al., 2015b) . With this ECL format, increased NF-L levels were reported in sera from RRMS patients (around 10 ng/L) (Disanto et al., 2016; Kuhle et al., 2016) and from FTD patients (around 31.5 ng/L in FTD versus 2.9 ng/L in controls) (Meeter et al., 2016) . In both cases, serum and CSF NF-L levels were highly correlated. The UmanDiagnostics NF-L ELISA kit has also been transferred to the ultrasensitive SIMOA platform and used in a small pilot study in PSP patients to show that blood NF-L levels can discriminate PSP patients (31 ng/L) from control subjects (17.5 ng/L) (Rojas et al.,2016) . Using the same approach, Rohrer et al. (Rohrer et al., 2016) reported high blood NF-L levels in FTD patients (77 ng/L) compared to controls (19 ng/L).
In p25 mice, probably due to the very high levels of NF-L in CSF, we were able to detect NF-L in serum using the conventional NF-L ELISA format (lower detection limit of NF-L with UmanDiagnostics NF-light® assay is 31 ng/L). However, serum NF-L levels were 20 to 76-fold lower than CSF NF-L levels. Bacioglu et al. (Bacioglu et al., 2016) (Table S1) , together with the fact that serum levels were 20 to 76-fold lower than CSF levels suggest that, in p25 mice, most of the NF-L in the blood originates from the CNS. Our ROC analyses also validate CSF NF-L and serum NF-L as relevant biomarkers, able to discriminate "non-neurodegenerative" control mice from "neurodegenerative" p25 mice and demonstrate that NF-L could be a relevant marker of the progressive and rapid neurodegeneration in this preclinical model.
In conclusion, we have shown that CSF and serum NF-L can be used as a biomarker of neurodegeneration in p25 mice. Our data provide additional evidence that CSF and serum NF-L levels are of interest to be further evaluated as both potential translational dynamic biomarkers of neurodegeneration and as pharmacodynamic biomarkers to evaluate the efficacy of new neuroprotective agents in preclinical animal models and in clinical studies.
29 significant group and sex effect, except for brain weights for which no sex effect was evidenced. Winer analysis was then performed followed by a Newman-Keuls test on ranktransformed data, except for brain weights (raw data) + p<0.05, ++ p<0.01 and +++ p<0.001.
Figure legends
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30 (E) Correlation between CSF and serum NF-L levels in induced p25 mice (Ctl animals were excluded from the analysis). A Spearman coefficient of correlation was calculated (r=0.352; p=0.0277; n=39 animals). 
Supplementary methods
Statistical analysis
ON study
In the ON study (Fig. 1) , data from 11 Ctl (WtxHe, 4 males and 7 females,) and 42 p25
(HexHe, 15 males and 27 females) mice were analysed. Statistical analysis was performed to evaluate either the effect of transgene induction in comparison to control (Ctl) mice or the effect of duration of induction. To evaluate the effect of transgene induction, a two-sided two-way analysis of variance with factors "Group" and "Sex" was performed either on raw data (for parameter "brain weight") or, when normality and/or homogeneity of variances hypotheses were not fulfilled, on rank-transformed data (for all other parameters). When appropriate, it was followed by a Dunnett's test to validate the pathology induction by comparing the Ctl (WtxHe) group to the p25 (HexHe) groups.
To study the effect of duration of the induction of neurodegeneration, a two-sided two-way analysis of variance with factor "Group" and "Sex" was also performed. Then, when appropriate, a Winer analysis followed by a Newman-Keuls test to compare the p25 groups with the induction 3, 4, 5 and 6wON pairwise was performed.
ON-OFF study
In the ON-OFF study (Fig. 2, 3 and 4) , data from 12 Ctl (6 male and 6 female) and 60 p25 mice (30 male and 30 female) were analysed; 1 male mice died before CSF sampling. The effect of duration of the transgene induction and the impact of switching off the transgene were analysed in p25 (HexHe) male mice only. Rank-transformed data were used, except for the parameter "brain weight" for which no transformation was needed. Control mice were
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39 excluded for the statistical analysis. In p25 mice, a one-way analysis of variance was performed, followed by a Newman-Keuls multiple comparison test. To analyse the effect of switching off the transgene, the 2wON+3wOFF group was compared to the 2wON and 5wON groups, and the 3wON+2wOFF group was compared to the 3wON and 5wON groups.
In addition, Spearman correlation coefficients were calculated between the parameter "CSF NF-L" and the parameters "brain weight", "p25-GFP", "serum NF-L", "NeuN" and "Fluoro-Jade B", respectively. Similarly, Spearman correlation coefficients were calculated between the parameter "Serum NF-L" and the parameters "NeuN" and "Fluoro-Jade B".
ROC curves
Area Under ROC curve and associated statistics were calculated using data pooled from 65
Ctl and 118 p25 mice, with pROC R package, R v3.1.1, pROC v1.7.3 (Robin et al., 2011) .
Optimal threshold was determined by the Youden method, which maximizes sum of sensitivity and specificity (Youden, 1950) .
NanoLC-MS/MS analysis
Protein sample processing
Mass spectrometry analysis of immuno-captured NF-L was performed. 400µl of CSF from 9-month-old Thy- Tau22 The resulting peptides were extracted from the gel by incubation in successively three buffers: 50% acetonitrile, 0.2% formic acid; 75% acetonitrile, 0.2% formic acid and acetonitrile/ethanol (1:1). The three collected extractions were pooled with the initial digestion supernatant, dried in SpeedVac, and resuspended with 50 µl of 2% acetonitrile, 0.05% TFA.
NanoLC-MS/MS Analysis
The resulting peptides were analysed by nanoLC-MS/MS using an Ultimate3500 RSLC System (Dionex) coupled to a QExactive Plus mass spectrometer (Thermo Scientific) equipped with a nanoelectrospray source in one injection. Twenty µl of each sample were loaded onto a C-18 precolumn (300 µm inner diameter X 5 mm; Dionex) at 20 µl/min in 2% acetonitrile, 0.05% TFA. After 3 min of desalting, the precolumn was switched online with the analytical C18 column (75 µm inner diameter X 15 cm, 100Å, 2µm; Acclaim PepMap RSLC, Dionex) equilibrated in 96% solvent A (0.2% formic acid) and 4% solvent B (80% acetonitrile, 0.2% formic acid). The peptides were eluted using a 6 to 33% gradient of solvent B during 60 min at 300 nl/min flow rate. The mass spectrometer was operated in the data-dependent mode 
